Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.
Januszewski AS, Young HK, Ong KL, Li L, O'Connell RL, Lyons TJ, Kelly C, Zaharieva DP, Sullivan DR, Scott RS, Keech AC, Jenkins AJ; FIELD Study Investigators. Januszewski AS, et al. Among authors: scott rs. J Diabetes Investig. 2024 Nov;15(11):1663-1668. doi: 10.1111/jdi.14290. Epub 2024 Aug 22. J Diabetes Investig. 2024. PMID: 39171747 Free PMC article. Clinical Trial.
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC; FIELD investigators. Cao JY, et al. Among authors: scott rs. Diabetes Obes Metab. 2020 Aug;22(8):1388-1396. doi: 10.1111/dom.14046. Epub 2020 Apr 22. Diabetes Obes Metab. 2020. PMID: 32243036 Clinical Trial.
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.
Ong KL, Wu L, Januszewski AS, O'Connell R, Xu A, Scott RS, Sullivan DR, Rye KA, Li H, Ma RC, Li L, Gebski V, Jenkins AJ, Jia W, Keech AC. Ong KL, et al. Among authors: scott rs. Diab Vasc Dis Res. 2021 Jul-Aug;18(4):14791641211032547. doi: 10.1177/14791641211032547. Diab Vasc Dis Res. 2021. PMID: 34275349 Free PMC article. Clinical Trial.
Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes.
Jenkins AJ, O'Connell RL, Januszewski AS, Webster AC, M E Davis T, Jardine MJ, Scott RS, Taskinen MR, Keech AC; FIELD Trial Study Group. Jenkins AJ, et al. Among authors: scott rs. Diabetes Res Clin Pract. 2024 Apr;210:111612. doi: 10.1016/j.diabres.2024.111612. Epub 2024 Mar 11. Diabetes Res Clin Pract. 2024. PMID: 38479447 Free article.
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Davis TM, et al. Among authors: scott rs. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. Diabetologia. 2011. PMID: 21052978 Clinical Trial.
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. Ong KL, et al. Among authors: scott rs. Diabetologia. 2015 Mar;58(3):464-73. doi: 10.1007/s00125-014-3458-7. Epub 2014 Nov 26. Diabetologia. 2015. PMID: 25425220 Clinical Trial.
268 results